Peer-Reviewed Paper Demonstrates the Benefits of Dropless Cataract Surgery

Source: Imprimis Pharmaceuticals

Imprimis Pharmaceuticals, an ophthalmology-focused pharmaceutical company, today announced the publication of a dropless therapy article in the peer-reviewed journal, Current Pharmaceutical Design. Dropless cataract surgery is a single-use, injectable combination of antibiotic and steroid formulation administered at the end of cataract surgery to essentially eliminate the need for post-surgery eye drops. The authors provide a retrospective review of data and efficacy of the Dropless approach, examine the transzonular via cannula injection technique, and discuss the benefits of dropless therapy to patients, physicians and their staff.

Several findings of the study included:

  1. Compliance issues are diminished with dropless therapy compared to standard post-surgery topical drop regimens. Lack of patient adherence to topical regimens are due to “drop phobia” and improper instillation of the drops especially in elderly patients with tremors, poor near vision and lack of dexterity. The article refers to a recent study showing more than 90% of patients incorrectly administered eye drops following cataract surgery. High costs may also deter some patients from filling all of their prescribed medications.       
  2. Cost savings to patients can range from $200 to $600 per cataract procedure. As health care shifts toward capitated care, the authors believe it is essential to use safe, efficacious and cost-effective therapy, such as dropless.  
  3. Staff time is significantly reduced without patient, insurance and pharmacy callbacks about eye drop substitutions and confusion over topical regimens. Jeffrey T. Liegner, MD, one of the authors of the paper, calculates that callbacks require an estimated 3,000 staff hours annually, or 1.5 full-time equivalents. Although staff time is significantly reduced, dropless requires educating patients about the procedure, why drops are not being prescribed and explaining the perception of floaters following surgery until excellent vision is experienced.    
  4. A retrospective review of dropless therapy cases found no postoperative endophthalmitis. Post-surgery infection and inflammation rates were similar to reported rates with other alternative prophylactic therapies, such as topical drops
  5. There have been no reported major intraoperative complications associated with the transzonular injection technique.

The authors concluded, “We believe that injection of needed medications at the time of surgery is an important change in the doctor-patient relationship. Rather than depending on the patient to take the necessary steps to obtain a good result, the surgeon can administer the drugs directly, gaining greater certainty that the proper dose will be achieved and gaining greater confidence in the outcome. It has been our experience that patients very much appreciate the opportunity to reduce or eliminate eye drops after surgery.”

John Saharek, Imprimis’ Chief Commercial Officer, stated, “We are pleased with the results of this peer-reviewed paper demonstrating the significant benefits of dropless therapy. The authors are pioneers in the field of cataract surgery and we appreciate their time and dedication to retrospectively evaluating the extensive body of clinical data that was needed to substantiate this well-documented overview of dropless cataract surgery. We continue to capture market share as more and more physicians understand the benefits of dropless as a prophylactic alternative to improve the patient experience, eliminate their own concerns about compliance and help lower costs for patients. We expect adoption rates will continue to rise with the opportunity to now acquire dropless therapy from our new state of the art FDA-registered 503B outsourcing facility.”

“Dropless Cataract Surgery: An Overview” was authored by Richard L. Lindstrom, MD, M. Stewart Galloway, MD, Andrzej Grzybowski, MD, PhD, MBA, and Jeffrey T. Liegner, MD and is available online to subscribers. To request a copy, please contact CC Song at csong@imprimispharma.com. For more information about Dropless Therapy, visit www.GoDropless.com.

Richard L. Lindstrom, MD, is an Imprimis board member, consultant, and investor; M. Stewart Galloway, MD, is an Imprimis consultant; and Jeffrey T. Liegner, MD, is an Imprimis consultant.  Andrzej Grzybowski, MD, PhD, MBA, has no affiliation to the company.  

Related Content


5 Myths About Ocular Allergies

Source: Medscape


Study: Hormone Replacement Therapy May Protect Against Eye Disease

Source: American Academy of Ophthalmology